Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) has earned an average recommendation of “Hold” from the seven ratings firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $4.49.
A number of research firms recently commented on SNSS. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.50 price target for the company in a report on Saturday, August 11th.
A number of large investors have recently bought and sold shares of SNSS. Millennium Management LLC raised its holdings in Sunesis Pharmaceuticals by 594.4% during the 1st quarter. Millennium Management LLC now owns 106,599 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 91,248 shares during the last quarter. Spark Investment Management LLC bought a new stake in Sunesis Pharmaceuticals during the 1st quarter valued at $204,000. Finally, Wells Fargo & Company MN raised its holdings in Sunesis Pharmaceuticals by 38.4% during the 1st quarter. Wells Fargo & Company MN now owns 64,367 shares of the biopharmaceutical company’s stock valued at $175,000 after buying an additional 17,853 shares during the last quarter. Institutional investors own 43.81% of the company’s stock.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.04. analysts predict that Sunesis Pharmaceuticals will post -0.89 earnings per share for the current year.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
See Also: Tariff
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.